NICE rejects Novartis's Xolair for paediatric asthma
This article was originally published in Scrip
Executive Summary
The National Institute for health and Clinical Excellence (NICE), the heath technology appraisal body for England and Wales, is still poised to decline Novartis's Xolair for treating severe persistent allergic asthma in children aged between six and 11 years on the NHS.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.